Quetiapine Efficacy and Safety in Psychotic Disorders

Efficacy in Specific Populations

• The American Academy of Child and Adolescent Psychiatry recommends quetiapine for youth with schizoaffective or bipolar disorder, as well as adolescents with schizophrenia and acute psychotic episodes 1
• The American Academy of Child and Adolescent Psychiatry prefers newer atypical antipsychotics like quetiapine over first-generation antipsychotics for children with intellectual disability and psychotic disorders due to reduced extrapyramidal symptoms risk 2

Safety Considerations in Older Adults

• The American College of Radiology advises careful risk-benefit assessment when using quetiapine in elderly patients with dementia-related psychosis due to increased mortality risk 3, 4

Efficacy in Delirium-Associated Delusions

• The Annals of Oncology suggests quetiapine may offer benefit in symptomatic management of delirium, though evidence level is lower than for primary psychotic disorders 5
• The Annals of Oncology notes quetiapine's sedating properties can be advantageous in hyperactive delirium 5

Treatment of Delusions with Quetiapine

Introduction to Quetiapine

• Quetiapine may offer benefit in symptomatic management of delirium-associated delusions, with a lower evidence level (Level V, Grade C) compared to primary psychotic disorders 6, 7.

Special Clinical Contexts

• The American Academy of Child and Adolescent Psychiatry recommends adequate therapeutic trials, requiring sufficient dosages over 4-6 weeks, with documentation of target symptoms and treatment response 8.

Key Safety Advantages for Delusion Treatment

• Quetiapine demonstrates a placebo-level incidence of extrapyramidal symptoms (EPS) at all doses, allowing confident dose escalation without increasing EPS risk 8.
• When metabolic risk is a major concern, quetiapine is preferred over olanzapine, causing significantly less weight gain and metabolic dysfunction 8.